Biography for Tracy Staton
Tracy Staton is the editor of FiercePharma. She has been a freelance writer for five years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Vivus says it's laying off 20 staffers to cut its losses as the obesity drug Qsymia continues to flounder. Launched last year, Qsymia brought in just $6.4 million for the third quarter, far from the lofty sales projected as the drug neared FDA approval. And with the drug still struggling for a market foothold, analysts worry that Vivus will have a hard time attracting a partner that can apply its marketing savvy to the job.
As more and more baby boomers have signed on for testosterone testing--and, in turn, therapy--worries about the safety of testosterone-boosting drugs have grown. Now, a new study in the Journal of the American Medical Association puts some numbers to that concern.
Novartis and Pfizer are in the process of spinning off units. Abbott Laboratories set its pharma business free at the beginning of this year. Why wouldn't Merck decide to join the slim-down club?
Novartis has brought its job-cutting sword to the U.K., with plans to shutter an R&D site in Horsham. Up to 371 jobs are expected to disappear there. But that's not all. The Swiss drugmaker also plans to shed as many as 72 marketing and sales jobs.
U.K. officials are finally taking the wraps off their new drug-pricing plan. The pharma industry has been waiting for the update to go public--but branded drugmakers are likely to wish they could wait longer. Under the new 5-year agreement, drugmakers will suffer new spending caps beginning next year.
Shire shares spiked to an all-time high after the company revealed new data showing its ADHD drug Vyvanse was effective at treating binge eating disorder.
Regeneron once again beat expectations with its quarterly earnings. And once again, the company raised its forecast for Eylea, the vision-loss drug that's fueling much of its growth. But once again, Regeneron said that sales growth for Eylea was slowing down as patients use fewer doses.
Endo Health Solutions needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company inked a deal to buy Canada's Paladin Labs for $1.6 billion.
It looks as if Novartis has had enough of the animal kingdom. According to Bloomberg's sources, the Swiss drugmaker is leaning toward a sale or spinoff of its animal health unit as a first move toward a slimmer, more focused company.
The dust hasn't settled after ex-CEO Jeremy Levin's quick-and-dirty departure from Teva Pharmaceutical Industries. In fact, the dust just keeps getting stirred up as more details emerge about the company's inner workings. Meanwhile, the company is trying to get the wagon train moving again by asking the U.S. Supreme Court to block generic versions of its top-selling multiple sclerosis drug, Copaxone.